19 related articles for article (PubMed ID: 38698843)
1. Effect of body mass index and cholesterol-rich apolipoprotein-B-containing lipoproteins on clinical outcome in NSCLC patients treated with immune checkpoint inhibitors-based therapy: A retrospective analysis.
Hu Z; Zheng Y; Zheng J; Wang Y; Liao J; Liu Z; Li J; Cui H
Cancer Med; 2024 Jun; 13(11):e7241. PubMed ID: 38819098
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of CT-determined sarcopenia in older patients with advanced squamous cell lung cancer treated with programmed death-1 inhibitors.
Ying L; Xu L; Yang J; Zhang Q
Sci Rep; 2024 May; 14(1):12025. PubMed ID: 38797769
[TBL] [Abstract][Full Text] [Related]
3. Impact of concurrent medications on the outcome of immunotherapy in non-small cell lung carcinoma.
Yamada J; Fukui T; Yatani A; Mimura C; Fukuda K; Hazama D; Katsurada N; Nagano T; Yamamoto M; Tachihara M
Thorac Cancer; 2024 May; 15(15):1228-1236. PubMed ID: 38622898
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Non-small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?
Li Y; Gong B; Guo Y; Liu W; Chen C; Jiang S; Pan F; Song J; Yang L; Zhou G
BMC Cancer; 2024 Apr; 24(1):535. PubMed ID: 38671373
[TBL] [Abstract][Full Text] [Related]
7. The impact of pulmonary artery to ascending aorta diameter ratio progression on the prognosis of NSCLC patients treated with immune checkpoint inhibitors.
Gong B; Li Y; Guo Y; Wang J; Liu W; Zhou G; Song J; Pan F; Yang L; Liang B
Front Immunol; 2024; 15():1302233. PubMed ID: 38348049
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors.
Lou J; Gong B; Li Y; Guo Y; Li L; Wang J; Liu W; You Z; Zhang H; Pan F; Liang B; Yang L; Zhou G
Front Immunol; 2024; 15():1332303. PubMed ID: 38698843
[TBL] [Abstract][Full Text] [Related]
10. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
